Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-15 10:35 am Sale | 13G | Terns Pharmaceuticals Inc. TERN | Point72 Asset Management L.P. | 2,894,093 3.500% | -1,027,133 (-26.19%) | View |
| 2024-11-14 7:00 pm Purchase | 13G | Terns Pharmaceuticals Inc. TERN | Vivo Capital Fund VIII L.P. | 4,597,243 5.400% | 4,597,243 (New Position) | View |
| 2024-11-14 5:51 pm Sale | 13G | Terns Pharmaceuticals Inc. TERN | Venrock Healthcare Capital Partners III L.P. | 3,516,889 4.990% | -980,228 (-21.80%) | View |
| 2024-11-14 4:15 pm Sale | 13G | Terns Pharmaceuticals Inc. TERN | Fairmount Funds Management LLC | 0 0.000% | -6,632,015 (Position Closed) | View |
| 2024-11-14 3:41 pm Sale | 13G | Terns Pharmaceuticals Inc. TERN | SUVRETTA CAPITAL MANAGEMENT LLC | 0 0.000% | -5,837,126 (Position Closed) | View |
| 2024-11-14 3:30 pm Purchase | 13G | Terns Pharmaceuticals Inc. TERN | Soleus Capital Master Fund L.P. | 6,223,544 7.300% | 2,882,424 (+86.27%) | View |
| 2024-11-08 2:17 pm Unchanged | 13G | Terns Pharmaceuticals Inc. TERN | BlackRock Inc. BLK | 4,698,771 5.600% | 0 (Unchanged) | View |
| 2024-11-05 4:15 pm Sale | 13G | Terns Pharmaceuticals Inc. TERN | INTEGRATED CORE STRATEGIES (US) LLC | 1,628,534 1.900% | -1,851,096 (-53.20%) | View |
| 2024-10-24 2:02 pm Purchase | 13G | Terns Pharmaceuticals Inc. TERN | BlackRock Inc. BLK | 4,698,771 5.600% | 1,577,906 (+50.56%) | View |
| 2024-09-16 8:29 pm Unchanged | 13D | Terns Pharmaceuticals Inc. TERN | ORBIMED ADVISORS LLC | 7,562,971 9.000% | 0 (Unchanged) | View |
| 2024-07-22 4:18 pm Purchase | 13G | Terns Pharmaceuticals Inc. TERN | CITADEL ADVISORS LLC | 3,410,764 5.300% | 3,410,764 (New Position) | View |
| 2024-07-18 5:33 pm Sale | 13D | Terns Pharmaceuticals Inc. TERN | ORBIMED ADVISORS LLC | 7,562,971 11.700% | -56,164 (-0.74%) | View |
| 2024-06-07 1:30 pm Sale | 13G | Terns Pharmaceuticals Inc. TERN | BlackRock Inc. BLK | 3,120,865 4.800% | -288,113 (-8.45%) | View |
| 2024-06-07 08:30 am Purchase | 13G | Terns Pharmaceuticals Inc. TERN | Soleus Capital Master Fund L.P. | 3,341,120 5.200% | 3,341,120 (New Position) | View |
| 2024-03-07 4:15 pm Purchase | 13G | Terns Pharmaceuticals Inc. TERN | Point72 Asset Management L.P. | 3,921,226 6.300% | 3,921,226 (New Position) | View |
| 2024-02-14 8:38 pm Purchase | 13G | Terns Pharmaceuticals Inc. TERN | Venrock Healthcare Capital Partners III L.P. | 4,497,117 7.300% | 789,226 (+21.29%) | View |
| 2024-02-14 3:47 pm Purchase | 13G | Terns Pharmaceuticals Inc. TERN | Fairmount Funds Management LLC | 6,632,015 9.900% | 1,362,728 (+25.86%) | View |
| 2024-02-14 08:57 am Purchase | 13G | Terns Pharmaceuticals Inc. TERN | Deep Track Capital LP | 6,100,000 9.870% | 2,540,000 (+71.35%) | View |
| 2024-02-13 5:21 pm Unchanged | 13G | Terns Pharmaceuticals Inc. TERN | LAV Biosciences Fund V L.P. | 2,901,566 4.700% | 0 (Unchanged) | View |
| 2024-02-13 11:44 am Purchase | 13G | Terns Pharmaceuticals Inc. TERN | SUVRETTA CAPITAL MANAGEMENT LLC | 5,837,126 9.500% | 2,388,851 (+69.28%) | View |